Financial Performance and Operating Leverage in Selected Indian Pharmaceutical Firms
This descriptive study examines how revenue growth, operating profitability and the observed sensitivity of EBITDA to revenue differ across five purposively selected listed Indian pharmaceutical firms (Piramal Pharma, Ajanta Pharma, Laurus Labs, Neuland Laboratories and Innova Captab) over FY2022–FY2026, and analyses Piramal Pharma’s FY2026 results in more detail. It uses audited consolidated results, revenue CAGRs, calculated EBITDA margins (excluding other income), margin variability, an ex post EBITDA-based operating-leverage proxy and a DuPont decomposition of return on equity. Revenue CAGRs ranged from 7.8% to 20.8%. Mean calculated EBITDA margins were 25.9% (Ajanta), 23.6% (Neuland) and 23.1% (Laurus), against 13.7% (Innova) and 12.8% (Piramal). Firms described as having stronger differentiated capabilities generally recorded higher average margins; this association does not establish causality. In FY2026 Piramal’s company-reported EBITDA fell 28.2% on a 3.1% revenue decline and PAT turned to a loss of INR 326 crore; an EBITDA-to-PAT bridge shows several contributing items, and return on average equity fell from 1.14% to −4.00%, mainly through net margin. Findings are limited to the sample, and MSME evidence is treated as context only.
Authors
- Shirly Abraham
- Adit Vijay Bhoite
Publication Details
- Journal
- International Journal of Creative and Open Research in Engineering and Management
- Published
- 2026-11-17
- DOI
- https://doi.org/10.55041/ijcope.v2i11.093
- Primary Topic
- Financial Analysis and Corporate Governance
- Type
- article
- Field-Weighted Citation Impact
- 0.00